Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin

References

• Hanon OAP, Belmin J, Collet JP, et al. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch Cardiovasc Dis 2013;106:302-23
   Google Scholar
• Fery-Lemonnier E. La prévention et la prise en charge des accidents vasculaires cérébraux en France: Synthèse du rapport à Madame la ministre de la santé et des sports. Ministere De La Sante Et Des Sports, 2009. Available at: http://www.sante.gouv.fr/IMG/pdf/AVC_synthese_seule_rapport_final_vf.pdf
   Google Scholar
• Chevreul K, Durand-Zaleski I, Gouepo A, et al. Cost of stroke in France. Eur J Neurol 2013;20:1094-100
   PubMed Web of Science ®Google Scholar
• ISMAAP. International Self Monitoring Association of oral Anticoagulated patients. Available at: http://www.ismaap.org
   Google Scholar
• Bassand JP. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace 2012;14:312-24
   PubMed Web of Science ®Google Scholar
• Fauchier L, Taillandier S, Clementy N. [Antithrombotic management in atrial fibrillation]. Rev Prat 2013;63:199, 201-6
   Google Scholar
• Le Reste JY CB, Le Floch B, Nabbe P, et al. There are considerable drawbacks to oral anticoagulant for monitoring patients at home which should lead family physicians to discuss alternative or enhanced solutions: a cross-sectional study. BMC Cardiovasc Disord 2013;13:71
   Google Scholar
• Liard F, Le Heuzey JY, Aliot E, et al. [Atrial fibrillation and anticoagulation: general practitioner, cardiologist and patient's points of view]. Presse Med 2013;42:e259-70
   Google Scholar
• Mabo P, Leenhardt A, Jaillon P, et al. [Management of atrial fibrillation in France: the observational FACTUEL study]. Ann Cardiol Angeiol (Paris) 2009;58:151-8
   Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17
   PubMed Web of Science ®Google Scholar
• Heidbuchel HPV, Alings M, Antz M, et al. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34:2094-106
   PubMed Web of Science ®Google Scholar
• Elewa HF, Deremer CE, Keller K, et al. Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. J Thromb Thrombolysis 2013 (epub ahead of print)
   Google Scholar
• Choi JC, Dibonaventura MD, Kopenhafer L, et al. Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation. Patient Prefer Adherence 2014;8:167-77
   PubMed Web of Science ®Google Scholar
• Attaya S, Bornstein T, Ronquillo N, et al. Study of warfarin patients investigating attitudes toward therapy change (SWITCH Survey). Am J Ther 2012;19:432-5
   Google Scholar
• Dervaux B, Baseilhac E, Fagon JY, et al. Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012. Therapie 2013;68:253-63
   Web of Science ®Google Scholar
• Dorian P, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J 2014 (epub ahead of print)
   Google Scholar
• Lip GY, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther 2014;36:192-210
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
   PubMed Web of Science ®Google Scholar
• Haute autorité de santé (HAS). A methodological guide. Choices in methods for economic evaluation. Department of Economics and Public Health Assessment, 2012. Available at: http://www.has-sante.fr
   Google Scholar
• Cotte FE, Chaize G, Kachaner I, et al. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France. J Stroke Cerebrovasc Dis 2014;23:e73-83
   PubMed Web of Science ®Google Scholar
• Ministry of Health. National Hospital Tariff. Official Journal of the French Republic. 2011. Available at: http://www.journal-officiel.gouv.fr.
   Google Scholar
• Cohen A, Dallongeville J, Durand-Zaleski I, et al. Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch Cardiovasc Dis 2010;103:376-87
   Google Scholar
• Pricing Comittee (CEPS). Drug price database for France. Available at: http://www.medicprix.sante.gouv.fr. Last accessed 31st December 2013
   Google Scholar
• National Health Insurance Fund for Salaried Worker (CNAMTS). National tariffs for biological and nursing acts. 2011. Available at: http://www.ameli.fr
   Google Scholar
• Haute autorité de santé (HAS). Fibrillation auriculaire. Available at: www.has-sante.fr. Accessed Juillet 200.
   Google Scholar
• Ministry of Health. Prevention and management of stroke in France. 2009. Available at: http://www.sante.gouv.fr/IMG/pdf/AVC_rapport_final_vf.pdf
   Google Scholar
• Sullivan P, Slejko J, Sculpher M, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making 2011;31:800-4
   PubMed Web of Science ®Google Scholar
• Gage BF CA, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. JAMA Intern Med 1996;156:1829-36
   Google Scholar
• Caro JJ, Nord E, Siebert U, et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ 2010;19:1117-27
   PubMed Web of Science ®Google Scholar
• Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013;127:2166-76
   PubMed Web of Science ®Google Scholar
• Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:7119
   Google Scholar
• Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health 2013;16:498-506
   PubMed Web of Science ®Google Scholar
• Harrington AR, Armstrong EP, Nolan PE, Jr., et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81
   PubMed Web of Science ®Google Scholar
• Pink J, Pirmohamed M, Hughes DA. Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. Clin Pharmacol Ther 2013;94:269-76
   Google Scholar
• Psaty BM, Prentice RL. Minimizing bias in randomized trials: the importance of blinding. JAMA 2010;304:793-4
   Google Scholar
• Carrasco J, Cotté FE, Duprat Lomon I, et al. Anticoagulation treatment with VKA in France, Italy, Germany, Spain and United Kingdom. Results from the React AF study. Value in Health 2013;16:A516
   Google Scholar
• Lip GY, Larsen TB, Skjoth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012;60:738-46
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:480-6
   PubMed Web of Science ®Google Scholar
• Davis NJ, Billett HH, Cohen HW, et al. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother 2005;39:632-6
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104
   PubMed Web of Science ®Google Scholar